Intellipharmaceutics earns FDA approval for generic epilepsy drug

Toronto-based Intellipharmaceutics International earned Food and Drug Administration approval for its levetiracetam extended-release tablets.

Advertisement

Here are four things to know.

1. Levetiracetam is intended to treat partial onset seizures related to epilepsy.

2. The tablets are a generic equivalent to UCB’s brand name drug Keppra XR.

3. Sales of sales Keppra XR and all other generic equivalents already on the market in the U.S. reached about $168 million for the 12 months ended December 2015, according to Symphony Health Solutions.

4. Intellipharmaceutics has eight other new drug applications pending FDA review.

More articles on supply chain:

6 must-reads for supply chain leaders this week
UPS to offer Saturday ground delivery services
FDA approves new liquid drug for hypothyroidism

 

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.